Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher Sells 80,000 Shares of Stock

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) General Counsel Andrew Fisher sold 80,000 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $11.53, for a total value of $922,400.00. Following the completion of the sale, the general counsel now directly owns 359,999 shares of the company’s stock, valued at $4,150,788.47. The trade was a 18.18% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Andrew Fisher also recently made the following trade(s):

• On Tuesday, April 29th, Andrew Fisher sold 26,072 shares of Verona Pharma PLC American Depositary Share stock. The stock was sold at an average price of $8.98, for a total transaction of $234,126.56.

Verona Pharma PLC American Depositary Share Stock Down 2.2%

Verona Pharma PLC American Depositary Share stock opened at $90.92 on Thursday. The firm has a market capitalization of $7.74 billion, a price-to-earnings ratio of -45.46 and a beta of 0.21. The firm has a 50 day simple moving average of $73.21 and a 200 day simple moving average of $61.35. Verona Pharma PLC American Depositary Share has a 1-year low of $14.14 and a 1-year high of $94.45. The company has a current ratio of 8.86, a quick ratio of 8.73 and a debt-to-equity ratio of 1.07.

Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) last announced its quarterly earnings results on Tuesday, April 29th. The company reported $0.27 earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.49. The company had revenue of $98.65 million during the quarter, compared to analysts’ expectations of $41.47 million. On average, analysts predict that Verona Pharma PLC American Depositary Share will post -1.95 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on VRNA. Cowen began coverage on shares of Verona Pharma PLC American Depositary Share in a research report on Monday, April 28th. They set a “buy” rating on the stock. HC Wainwright boosted their target price on Verona Pharma PLC American Depositary Share from $85.00 to $90.00 and gave the stock a “buy” rating in a research note on Monday, June 2nd. Roth Capital reiterated a “buy” rating and issued a $116.00 target price (up from $92.00) on shares of Verona Pharma PLC American Depositary Share in a research note on Wednesday. TD Cowen began coverage on shares of Verona Pharma PLC American Depositary Share in a research note on Monday, April 28th. They set a “buy” rating and a $100.00 price target for the company. Finally, Jefferies Financial Group lifted their price target on shares of Verona Pharma PLC American Depositary Share from $95.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. Ten analysts have rated the stock with a buy rating, According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $91.11.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in VRNA. Renaissance Technologies LLC bought a new position in shares of Verona Pharma PLC American Depositary Share in the fourth quarter valued at approximately $720,000. Wells Fargo & Company MN lifted its stake in Verona Pharma PLC American Depositary Share by 27.2% in the 4th quarter. Wells Fargo & Company MN now owns 67,126 shares of the company’s stock worth $3,117,000 after purchasing an additional 14,362 shares in the last quarter. Northern Trust Corp bought a new position in Verona Pharma PLC American Depositary Share in the 4th quarter valued at $362,000. Cetera Investment Advisers boosted its holdings in Verona Pharma PLC American Depositary Share by 113.4% in the 4th quarter. Cetera Investment Advisers now owns 23,265 shares of the company’s stock valued at $1,080,000 after purchasing an additional 12,362 shares during the period. Finally, New York State Common Retirement Fund purchased a new position in shares of Verona Pharma PLC American Depositary Share during the 4th quarter valued at $285,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Verona Pharma PLC American Depositary Share Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.